GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sientra Inc (OTCPK:SIENQ) » Definitions » Beneish M-Score

Sientra (Sientra) Beneish M-Score : -4.05 (As of Apr. 28, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Sientra Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -4.05 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Sientra's Beneish M-Score or its related term are showing as below:

SIENQ' s Beneish M-Score Range Over the Past 10 Years
Min: -4.12   Med: -2.42   Max: 20.53
Current: -4.05

During the past 11 years, the highest Beneish M-Score of Sientra was 20.53. The lowest was -4.12. And the median was -2.42.


Sientra Beneish M-Score Historical Data

The historical data trend for Sientra's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sientra Beneish M-Score Chart

Sientra Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.86 -2.09 -3.07 -2.05 -3.56

Sientra Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.69 -3.56 -3.99 -4.12 -4.05

Competitive Comparison of Sientra's Beneish M-Score

For the Medical Devices subindustry, Sientra's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sientra's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sientra's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Sientra's Beneish M-Score falls into.



Sientra Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Sientra for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.841+0.528 * 1.366+0.404 * 1.1187+0.892 * 1.0246+0.115 * 0.825
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.7929+4.679 * -0.351761-0.327 * 1.1705
=-4.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep23) TTM:Last Year (Sep22) TTM:
Total Receivables was $29.61 Mil.
Revenue was 19.544 + 23.13 + 22.557 + 25.068 = $90.30 Mil.
Gross Profit was 10.029 + 12.615 + 12.147 + 3.231 = $38.02 Mil.
Total Current Assets was $86.51 Mil.
Total Assets was $139.93 Mil.
Property, Plant and Equipment(Net PPE) was $19.04 Mil.
Depreciation, Depletion and Amortization(DDA) was $7.24 Mil.
Selling, General, & Admin. Expense(SGA) was $77.74 Mil.
Total Current Liabilities was $152.09 Mil.
Long-Term Debt & Capital Lease Obligation was $4.13 Mil.
Net Income was -14.773 + -9.477 + -12.892 + -21.981 = $-59.12 Mil.
Non Operating Income was -3.177 + -0.044 + -0.057 + 4.753 = $1.48 Mil.
Cash Flow from Operations was -3.366 + -0.525 + -6.268 + -1.216 = $-11.38 Mil.
Total Receivables was $34.36 Mil.
Revenue was 22.57 + 21.513 + 21.398 + 22.648 = $88.13 Mil.
Gross Profit was 12.776 + 12.742 + 12.845 + 12.327 = $50.69 Mil.
Total Current Assets was $108.54 Mil.
Total Assets was $165.93 Mil.
Property, Plant and Equipment(Net PPE) was $20.95 Mil.
Depreciation, Depletion and Amortization(DDA) was $6.16 Mil.
Selling, General, & Admin. Expense(SGA) was $95.69 Mil.
Total Current Liabilities was $81.20 Mil.
Long-Term Debt & Capital Lease Obligation was $77.06 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(29.61 / 90.299) / (34.36 / 88.129)
=0.327911 / 0.389883
=0.841

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(50.69 / 88.129) / (38.022 / 90.299)
=0.57518 / 0.421068
=1.366

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (86.508 + 19.042) / 139.933) / (1 - (108.536 + 20.953) / 165.933)
=0.24571 / 0.219631
=1.1187

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=90.299 / 88.129
=1.0246

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(6.158 / (6.158 + 20.953)) / (7.235 / (7.235 + 19.042))
=0.22714 / 0.275336
=0.825

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(77.742 / 90.299) / (95.691 / 88.129)
=0.86094 / 1.085806
=0.7929

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((4.129 + 152.092) / 139.933) / ((77.063 + 81.201) / 165.933)
=1.116399 / 0.953783
=1.1705

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-59.123 - 1.475 - -11.375) / 139.933
=-0.351761

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Sientra has a M-score of -4.05 suggests that the company is unlikely to be a manipulator.


Sientra Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Sientra's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Sientra (Sientra) Business Description

Traded in Other Exchanges
Address
3333 Michelson Drive, Suite 650, Irvine, CA, USA, 92612
Sientra Inc is a part of the healthcare sector in the United States. Its business involves the provision of silicone gel breast implants for use in breast augmentation and breast reconstruction procedures. Its operating segments are Breast Products and miraDry. The Breast Products segment focuses on sales of breast implants, tissue expanders and scar management products under the brands OPUS, AlloX2, Dermaspan, Softspan, and BIOCORNEUM. The miraDry segment focuses on sales of the miraDry System and bioTips. Geographically, the firm generates a majority of its revenue from the United States.
Executives
Alexander W. Casdin director C/O IGNYTA, INC., 11095 FLINTKOTE AVENUE, SUITE D, SAN DIEGO CA 92121
Ronald Menezes director, officer: President and CEO 420 S. FAIRVIEW AVENUE, SUITE 200, SANTA BARBARA CA 93117
Van Hove Caroline F. director 420 S. FAIRVIEW AVENUE, SUITE 200, SANTA BARBARA CA 93117
Oliver Christian Bennett officer: General Counsel and VP 420 S. FAIRVIEW AVENUE, SUITE 200, SANTA BARBARA CA 93117
Andrew C Schmidt officer: Chief Financial Officer 1700 CARNEGIE AVE, SUITE 100, SANTA ANA CA 92705
Irina Erenburg director 420 S. FAIRVIEW AVENUE, SANTA BARBARA CA 93117
Nori Ebersole director C/O UROVANT SCIENCES, INC., 5151 CALIFORNIA AVENUE, SUITE 250, IRVINE CA 92617
Valerie J Miller officer: VP, Controller and Interim CFO
Paul Sean Little officer: Chief Financial Officer SIENTRA, INC., 420 SOUTH FAIRVIEW AVENUE, SUITE 200, SANTA BARBARA CA 93117
Jeffrey M Nugent director 1875 SOUTH GRANT STREET, SUITE 110, SAN MATEO CA 94402
Keith J Sullivan director C/O RELIANT TECHNOLOGIES, INC., 464 ELLIS STREET, MOUNTAIN VIEW CA 94043
Kevin C Oboyle director 5964 LA PLACE COURT, CARLSBAD CA 92008
Mary Fisher director C/O ACORDA THERAPEUTICS, INC., 15 SKYLINE DRIVE, HAWTHORNE NY 10532
Timothy Haines director, 10 percent owner 38 JERMYN STREET, LONDON X0 SW1Y 6DN
Philippe Schaison director C/O ACTAVIS PLC MORRIS CORP CENTER III, 400 INTERPACE PARKWAY, PARSIPPANY NJ 07054

Sientra (Sientra) Headlines

From GuruFocus

Q1 2021 Sientra Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q4 2021 Sientra Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q2 2023 Sientra Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Sientra Announces FDA-Clearance of Novel Portfinder� Technology

By sperokesalga sperokesalga 05-17-2023

Sientra Inc Annual Shareholders Meeting Transcript

By GuruFocus Research 02-09-2024

Q1 2023 Sientra Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q3 2022 Sientra Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q3 2020 Sientra Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024